Literature DB >> 28872674

The methylazoxymethanol acetate rat model: molecular and epigenetic effect in the developing prefrontal cortex: An Editorial Highlight for 'Epigenetic mechanisms underlying NMDA receptor hypofunction in the prefrontal cortex of juvenile animals in the MAM model for schizophrenia' on page 320.

Xiyu Zhu1, Felipe V Gomes1, Anthony A Grace1.   

Abstract

This Editorial highlights an article by Gulchina and colleagues in the current issue of the Journal of Neurochemistry, in which the authors describe molecular and epigenetic changes in the developing prefrontal cortex of the rats exposed to methylazoxymethanol acetate (MAM). They found an NMDAR hypofunction present in the prefrontal cortex of juvenile MAM rats which was associated with abnormal epigenetic regulation of the Grin2b gene. These changes may be related to early cognitive impairments observed in MAM rats and schizophrenia patients.
© 2017 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28872674      PMCID: PMC5679231          DOI: 10.1111/jnc.14133

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  17 in total

1.  Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes.

Authors:  Alexander W Bruce; Ian J Donaldson; Ian C Wood; Sally A Yerbury; Michael I Sadowski; Michael Chapman; Berthold Göttgens; Noel J Buckley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

Review 2.  Sensitive periods in epigenetics: bringing us closer to complex behavioral phenotypes.

Authors:  Corina Nagy; Gustavo Turecki
Journal:  Epigenomics       Date:  2012-08       Impact factor: 4.778

Review 3.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

Review 4.  Translating the MAM model of psychosis to humans.

Authors:  Gemma Modinos; Paul Allen; Anthony A Grace; Philip McGuire
Journal:  Trends Neurosci       Date:  2014-12-30       Impact factor: 13.837

Review 5.  Adolescent Stress as a Driving Factor for Schizophrenia Development-A Basic Science Perspective.

Authors:  Felipe V Gomes; Anthony A Grace
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

6.  Early life stress enhances behavioral vulnerability to stress through the activation of REST4-mediated gene transcription in the medial prefrontal cortex of rodents.

Authors:  Shusaku Uchida; Kumiko Hara; Ayumi Kobayashi; Hiromasa Funato; Teruyuki Hobara; Koji Otsuki; Hirotaka Yamagata; Bruce S McEwen; Yoshifumi Watanabe
Journal:  J Neurosci       Date:  2010-11-10       Impact factor: 6.167

7.  Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia.

Authors:  Yijuan Du; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

8.  NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia.

Authors:  Melissa A Snyder; Wen-Jun Gao
Journal:  Front Cell Neurosci       Date:  2013-03-27       Impact factor: 5.505

Review 9.  Epigenetic mechanisms in schizophrenia.

Authors:  Schahram Akbarian
Journal:  Dialogues Clin Neurosci       Date:  2014-09       Impact factor: 5.986

10.  REST-dependent epigenetic remodeling promotes the developmental switch in synaptic NMDA receptors.

Authors:  Alma Rodenas-Ruano; Andrés E Chávez; Maria J Cossio; Pablo E Castillo; R Suzanne Zukin
Journal:  Nat Neurosci       Date:  2012-09-09       Impact factor: 24.884

View more
  1 in total

1.  Preclinical characterization of AMPA receptor potentiator TAK-137 as a therapeutic drug for schizophrenia.

Authors:  Maiko Tanaka; Akiyoshi Kunugi; Atsushi Suzuki; Noriko Suzuki; Motohisa Suzuki; Haruhide Kimura
Journal:  Pharmacol Res Perspect       Date:  2019-05-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.